Several other equities research analysts have also commented on CTSO. ValuEngine lowered shares of Cytosorbents from a hold rating to a sell rating in a report on Monday, October 2nd. Maxim Group set a $12.00 price target on shares of Cytosorbents and gave the company a buy rating in a report on Thursday. Finally, HC Wainwright reaffirmed a buy rating and issued a $13.00 price target on shares of Cytosorbents in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $10.40.
Cytosorbents (NASDAQ:CTSO) traded up $0.15 during trading hours on Friday, reaching $6.70. 186,497 shares of the company’s stock traded hands, compared to its average volume of 146,956. Cytosorbents has a one year low of $3.30 and a one year high of $7.05. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. The stock has a market capitalization of $196.63, a price-to-earnings ratio of -17.63 and a beta of -0.53.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wealthcare Advisory Partners LLC acquired a new position in shares of Cytosorbents during the 3rd quarter worth about $365,000. Fortaleza Asset Management Inc. raised its position in shares of Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after purchasing an additional 10,500 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after purchasing an additional 22,500 shares during the last quarter. Hedge funds and other institutional investors own 8.65% of the company’s stock.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.